As allergic, IL-13 driven, asthma is the primary indication for therapeutic STAT6 siRNA, our rationale for this approach was based on findings that respiratory allergy is reflective of an integrated, systemic inflammatory disorder [17], [19], [20]. The gene discussed is STAT6; the disease is asthma.